Combined modality treatment of high-risk T1 bladder cancer: More effective than intravesical therapy, less radical than cystectomy

Abstract

Current treatment options for high-risk superficial T1-bladder cancer (grade 3, associated Tis, multifocality, tumor diameter > 5cm or multiple recurrences) include early cystectomy or the goal of organ-preservation by adjuvant intravesical therapy after transurethral resection (TURBT). We have evaluated the efficacy of adjuvant radiotherapy (RT) or radiochemotherapy (RCT) on local control, bladder-preservation, recurrence rate and long-term survival after TURBT of high-risk T1-bladder cancer.